NAD+ (NR) for Parkinson's: What the NADPARK Trials Show

Of all the conditions NAD+ supplements get attached to, Parkinson's disease (PD) is one of the few with real, registered human trials behind it — not just marketing. That makes it genuinely more interesting than the usual "boosts energy" claims. But it also makes it easy to overstate: the published trials are small, early-stage, and designed to answer "is this safe and does it reach the brain?" — not "does it slow Parkinson's?" Here's an honest accounting of what the NADPARK and NR-SAFE studies actually found, and what they pointedly did not.

Why researchers think NAD+ might matter in Parkinson's

The rationale isn't arbitrary. Parkinson's involves mitochondrial dysfunction and impaired cellular energy metabolism in vulnerable neurons, and NAD+ is central to how cells make energy and run mitochondrial and repair pathways. The hypothesis is that "topping up" NAD+ — using a precursor like nicotinamide riboside (NR) that the body can convert into NAD+ — might support those failing energy systems.

That idea has solid preclinical backing. In laboratory models, the NAD+ precursor NR rescued mitochondrial defects and reduced neuronal loss in induced-pluripotent-stem-cell (iPSC) and fruit-fly models of Parkinson's ¹. Reviews of the field now frame NAD+ augmentation as a plausible disease-modifying strategy for neurodegeneration worth testing — while being explicit that it remains unproven in patients ². So the starting point is a real mechanism and encouraging animal/cell data, not hype. The crucial question is whether any of it translates to people.

NADPARK: the landmark Phase I trial

The study that put NAD+ and Parkinson's on the map is NADPARK, a double-blind Phase I trial in Norway ³. Thirty newly diagnosed, treatment-naive PD patients received either 1,000 mg/day of oral NR or placebo for 30 days. Three findings stand out:

1. 1.It was safe and well tolerated over the month.
2. 2.It reached the brain. Using phosphorus MRI spectroscopy, the researchers measured a significant — but variable — increase in cerebral NAD levels, confirming oral NR can actually raise brain NAD+ in some people ³.
3. 3.Responders showed signals worth chasing. Patients whose brain NAD+ rose showed altered cerebral metabolism on PET imaging, and this was associated with mild clinical improvement; NR also nudged down inflammatory markers in blood and cerebrospinal fluid ³.

The authors' own conclusion is the right tone for this whole topic: their findings "nominate NR as a potential neuroprotective therapy" that warrants "further investigation in larger trials" ³. In plain terms: promising enough to keep studying, nowhere near proven.

NR-SAFE: how high can the dose go?

The obvious follow-up question — if some patients didn't raise brain NAD+ much, would a bigger dose help? — drove the NR-SAFE trial ⁴. This Phase I study gave 20 PD patients 1,500 mg of NR twice daily (3,000 mg/day — triple the NADPARK dose) or placebo for four weeks, with safety as the primary goal.

The high dose was well tolerated, with no moderate or severe adverse events, and it dramatically boosted the blood NAD+ metabolome — up to a roughly 5-fold rise in blood NAD+ ⁴. There was an improvement in total Parkinson's severity scores (MDS-UPDRS), but the authors were careful to flag a confounder: that change was also linked to how recently patients had taken their levodopa, so it cannot be cleanly credited to NR ⁴. They also noted a slight, transient rise in homocysteine — a reminder that high-dose precursor therapy isn't consequence-free and needs monitoring.

So NR-SAFE answered its actual question — high-dose NR is safe short-term and massively raises blood NAD+ — without answering the one patients care about most: does it change the course of the disease?

The honest gap: "raises NAD+" is not "treats Parkinson's"

This is the heart of it. Both trials succeeded at what they set out to do — establish safety, brain delivery, and target engagement. Neither was designed or powered to prove a clinical benefit, and the clinical signals seen so far were mild, variable, or confounded.

That distinction matters because the broader NAD+ literature is full of cases where the biomarker moves but the outcome doesn't. In aged human muscle, for instance, NR clearly augmented the NAD+ metabolome and produced anti-inflammatory signatures yet did not improve physical performance ⁵; chronic NR reliably raises NAD+ in healthy adults, too, without that automatically delivering felt benefits ⁶. Even within the PD program, a companion analysis found NR did not alter methylation homeostasis as some had hypothesized ⁷. "We raised NAD+" is a real achievement; it is simply not the same claim as "we slowed Parkinson's."

It's also worth noting how much of the optimism still rests on non-human work — the mitochondrial rescue was shown in cells and flies ¹, and much of the aging rationale comes from rodent studies such as long-term NMN mitigating age-related decline in mice ⁸. Animal and cell models are where good hypotheses come from; they are not where they're confirmed.

What this means if you or a family member has Parkinson's

A few honest takeaways:

• •NR is not an approved or established treatment for Parkinson's. The trials are early-phase and explicitly call for larger studies before any conclusion.
• •The genuinely encouraging part is mechanistic: oral NR can reach the brain and raise NAD+ there, and it's been safe in short trials — including at high doses. That's a real foundation for the larger trials now needed.
• •The clinical-benefit evidence is not yet there. Improvements seen so far were mild, inconsistent across patients, or confounded by Parkinson's medication timing.
• •This is firmly a talk-to-your-neurologist situation, not a self-experiment. PD care is individualized, high-dose precursors interact with the methylation system, and nothing here should change a treatment plan without a specialist.

Bottom line

The NADPARK and NR-SAFE trials are among the most legitimate human evidence in the entire NAD+ field: real, registered, placebo-controlled studies showing that oral nicotinamide riboside is safe in Parkinson's, reaches the brain, and raises NAD+ there — with early hints of metabolic and clinical effects in responders. But they are Phase I dose-finding and safety trials, not proof that NAD+ treats Parkinson's. The right reading is cautious optimism aimed at the larger trials these studies were designed to justify. For the bigger picture of where NAD+ supplementation is genuinely supported and where it isn't, see our pillar guide to the NAD+ evidence, our look at whether NAD+ is really anti-aging, the careful evidence review behind NAD+ and cancer, and a closely parallel "strong-in-rodents, untested-in-people" case in NAD+ and NMN for neuropathy.